Precision medicine
Eric Dishman, director of the All of Us Research Program, explains the goals of the landmark genomics initiative – and explains how his own personal experience with whole-genome sequencing has informed his work.
Development of evidence-based services for guiding treatment decisions within EHRs and care plan workflows is expected to be an outcome of two new acquisitions.
In fact, researchers said genetic sequencing could become less relevant in the near future.
No, that’s not a joke. It’s also about economic solvency and workforce productivity.
CRISPR-Cas9 could soon transform patient care, but process efficacy needs to be honed and delivery technology needs to be refined first.
Personalized care can reduce costs, prevent diseases, and bring joy back to doctors, but the healthcare system needs to learn how to adopt emerging technologies more quickly.
The director of the All of Us Research Program at the National Institutes of Health draws on hard-won experience as he works to the democratize the potential of genomic research.
While the industry is rapidly making progress on precision medicine, cultural, policy and regulatory changes are limiting momentum, industry leaders said at the Precision Medicine Summit on Monday.
Licensing partnership with 2bPrecise aims to bring genomics into the EHR workflow.
With the goal of enrolling 10,000 Americans by early autumn, Precision Medicine Initiative program head Eric Dishman said that NIH intends to scale up quickly.